MAPK1 and breast cancer: In many, ERK activation reflects the activity of mutated forms of ras. However, in breast cancer activating ras mutations are relatively rare, reported in only 5% of cases (Bos, 1989; Dickson et al, 1991), leading to the view that ras mutations do not have an important role in this disease.